Item 7.01. Regulation FD Disclosure.

Included as Exhibit 99.1 to this report is copy of a presentation that Lineage Cell Therapeutics, Inc. ("Lineage") intends to use in various meetings, commencing on January 23, 2023, with investors, securities analysts and others. The presentation, dated January 23, 2023 and incorporated herein by reference, addresses, among other things, information about Lineage, its product candidates and recent business developments.

The information contained in this Item 7.01, and in Exhibit 99.1 attached hereto, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section 18 or of Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). Furthermore, the information contained in this Item 7.01 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed by Lineage with the Securities and Exchange Commission pursuant to the Securities Act or the Exchange Act, whether filed before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description

99.1            Corporate Presentation dated January 23, 2023

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)



-2-

© Edgar Online, source Glimpses